**Jefferson Health – Israel Pilot and R&D Program Call for Proposals**

**May 19th – September 19th, 2022**

The *Israel Innovation Authority* (the Authority) and *Thomas Jefferson University* (TJU) invite interested Israeli companies to submit applications for research & development projects or pilot solutions in the healthcare-related technology field with TJU.

This call is open both to joint proposal for cooperation in R&D activities with TJU, and for pilot projects for companies that wish to pilot, scale-up and adapt their new innovative technologies and solutions.

TJU and the authority are seeking to advance healthcare by helping Israeli companies get the evidence and assistance they need to fine-tune their development and to enter and be successful in the United States’ healthcare market.

TJU would serve as a real-world living laboratory for the Israeli companies, where TJU clinical and research experts would work with Israeli startups to test and improve existing processes, services, or products; or to apply a new process to health care for the first time.

The goal of this collaboration is to accelerate the availability of medical innovations to the public, introduce Israeli healthcare technology to the U.S., and advance the development and deployment of discoveries for the benefit of patients everywhere**.**

The Authority provides resources to aid technology advancement for Israeli companies.

Jefferson is a large academic healthcare system that spans over Eastern Pennsylvania and Southern New Jersey. In addition to its traditional academic and clinical operations, Jefferson provides innovation-related expertise to companies to help advance clinical care and hospital operations.

The IIA and Jefferson recently concluded a successful pilot program selecting four Israeli startup companies to receive grants to develop their innovative products at the Jefferson Health ecosystem. Jefferson is excited to share their experience and templates developed to assure future productive collaboration with the new selected applicants under this Call for Proposals.

The following Jefferson strategic innovation assets and capabilities serve as a “sandbox” environment for emerging innovative digital health solutions and can among other things serve as a resource for Israeli companies:

* Vicki and Jack Farber Institute for Neuroscience
* Sidney Kimmel Cancer Center
* National Academic Center for Telehealth – Thomas Jefferson University
* Center for Digital Health & Data Science – Thomas Jefferson University
* Institute for Smart and Healthy Cities
* Wills Eye Institute

**Th**

**Focus Areas:**

The digital health themes of interest to TJU include:

* Neuroscience
* Computer brain interface
* Cancer
* Hospital at Home
* Heart Failure/Heart Transplant/Shock and Cardiac Rehabilitation
* Smart Aging in place
* Clinical trials and Virtual clinical trials
* Medical AI
* Digital Health
* Tele Health
* Connectivity
* Urban Mobility
* Health Education

**Deadline for submissions: 19/09/2022**

**What support do the Authority and TJU offer?**

Successful Israeli applicant companies will receive funding from the authority and in-kind services from TJU.

The authority can support R&D performing companies, registered and operating in Israel, with a grant of up to 50% of the approved Pilot or R&D Expenses Budget, according to its regulations and procedures.

* Research institutions as subcontractors to eligible companies.

When a project eventually results in sales of a product, service, or process, the financial support must be repaid in royalties to the *Israel Innovation Authority* according to its regulations. In general, royalties are paid at rates beginning at 3% of sales, depending on various criteria. Royalties are payable until 100% of the amount of the grant has been repaid with interest as provided in the applicable regulations. If the project does not result in sales, no repayment is required.

An appropriate agreement between successful applicant companies and TJU will need to be signed before project initiation.

**Requirements**

Cooperation proposals should be in line with the following requirements:

1. The participation of at least one company from each country is mandatory. Research institutes and other companies may participate as partners or subcontractors in the cooperation project, respecting the financing rules of each country.
2. The proposal should result in the development of an improved or new product or process with industrial application intended for commercialization in domestic and/or global markets, including proof of concept projects for technology-based solutions.
3. The new product / process should be innovative, have relevant market potential, technological risk and add value to the economies of both countries.
4. The project should demonstrate adequate balance and complementarity between the two partners in relation to the R&D phases.
5. The project should present a clear competitive advantage and differentiated value proposition as a result of cooperation between the participants of the two countries (increase of knowledge base, access to R&D infrastructure, new fields of application, for example).
6. Companies should present a strategy which, given their technological, commercial, and financial aspects, demonstrates their potential to introduce the new product / process into the markets of both countries and/or third countries.
7. Partners in the project must agree in advance on the allocation of intellectual property rights (IP) between companies, as well as the marketing strategy. This agreement should reflect a proportional allocation and a fair return for both partners in relation to their respective investments.
8. In a pilot project proposal, the IP rights will stay in the hands of the Israeli partner
9. Partners in Israel and in Brazil should be able to implement the project and finance their respective shares.
10. Any partnership whose cooperative R&D project is consistent with the above criteria may present it in this Call, in accordance with applicable national laws, rules, regulations and procedures.

**Process and Timeline**

|  |  |
| --- | --- |
| Program launch | 19/05/2022 |
| Agreement signing and submission to the Authority | 19/09/2022 |

**Contacts**

|  |  |
| --- | --- |
| **Jefferson Health**  Zvi Grunwald, MD  Executive Director, The Jefferson Israel Center, Thomas Jefferson University  Zvi.Grunwald@jefferson.edu | **Israel Innovation Authority**  Alan Hofman  Business Development Manager  +972-3-715-7987  [Alan.hofman@innovationisrael.org.il](mailto:Alan.hofman@innovationisrael.org.il) |